BRIDGE-DS study: a multicenter, observational, retrospective analysis of dapagliflozin and sitagliptin combination on modifiable cardiovascular risk factors in T2DM patients with ASCVD or high cardiovascular risk
{{output}}
Background: Atherosclerotic cardiovascular disease (ASCVD) is a major comorbidity among those with type 2 diabetes mellitus (T2DM) and requires effective management strategies. Few real-world evidence studies have established the... ...
